John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of CLL.
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of CLL.